New York v. Tele-Communications Inc., 1993 WL 527984 (S.D.N.Y. Sept. 14, 1993), 1993-2 Trade Cases P 70, 404
Defendant cable system operators, subsidiaries and a satellite cable supplier formed a monopoly in restraint of trade in the delivery of multichannel subscription television programming.
In the Matter of GlaxoSmithKline, PLC (Augmentin)
States alleged that GlaxoSmithKline fraudulently obtained patent protection for Augmentin and then delayed generic entry through sham patent litigation. Through this conduct, GlaxoSmithKline unlawfully maintained its monopoly over Augmentin. A $3.5 million multistate settlement for state proprietary claims was entered into by the participating states and GlaxoSmithKline.
In Re Relafen Antitrust Litigation
States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.
Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
In the Matter of Tri-County Hospital and Wadena Med. Center, No. C4-94-11900 (Ramsey Cty. Cr. Minn., Nov. 30, 1994)
State alleged hospital and large clinic sought to allocate the markets for x-ray equipment and colposcopy equipment.
U.S. and Texas, et al v. Oracle, Corporation, No.C-04 0807 (JCS )(N.D.Cal.2005)
Merger review of two of the most dominant vendors of high function Human Resource Management software and high function Financial Management Services software.
In the Matter of Warren Supply
Company tied satellite programming and other products to purchase of digital satellite systems.
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint
Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.
Minnesota v. Tim Amdahl Chevrolet Co., No. C3-93-676 (Winona Cty. Ct.)
Auto body repair shops fixed prices by providing sham estimates on competitors blank letterhead.
